repurposing semaglutide and liraglutide for alcohol use disorder GLP-1 Agonists Show Promise in Treating Substance Disorders A new clinical trial supported

Finally, the obesity paradox appears to have been dispelled

25 pouches per container (meant to be taken 6 days on, 1 day off)

While both peptides share the common goal of increasing the bodys natural growth hormone (GH) production, they work through fundamentally different biological mechanisms, which affects their clinical applications, side effect profiles, and suitability for different patients

Polymer Chemistry

You roll the tool over your scalp (beware, it doesn't feel good!) and create tiny micropunctures

Retatrutide: A Promising Option for Non-Diabetic Weight Loss in Clinical Trials Key Takeaways Retatrutide, a new triple receptor agonist, appears particularly promising as a non-diabetic weight loss agent because it targets glucagon, GLP-1, and GIP